

Supplementary Table S3. Demographic and clinical characteristics of metastatic colorectal cancer patients from cohort 8.

| Characteristics | Patients |
|---|-----------------|
| Size - no. | 6 |
| Age - years | |
| Median (range) | 61 (47- 81) |
| Sex - no. (%) | |
| Female | 3 (50) |
| Male | 3 (50) |
| ECOG-PS - no. (%) | |
| 1 | 5 (83) |
| 2 | 1 (17) |
| Primary tumour site - no. (%) | |
| Right colon | 1 (17) |
| Transverse colon (proximal two thirds) | 1 (17) |
| Left colon | 5 (83) |
| Sigmoid colon | 2 (33) |
| Rectosigmoid junction | 2 (33) |
| Rectum | 1 (17) |
| RAS status - no. (%) | |
| Mutated | 3 (50) |
| KRAS mutation | 3 (50) |
| No mutated | 3 (50) |
| BRAF status - no. (%) | |
| No mutated | 6 (100) |
| MMR status - no. (%) | |
| Preserved | 5 (83) |
| Deficient | 1 (17) |
| MLH1/PMS2 deficient | 1 (17) |
| TNM stage at diagnosis - no. (%) | |
| I | 1 (17) |
| IV | 5 (83) |
| Site of metastases - no. (%) | |
| Liver | 5 (83) |
| Lung | 3 (50) |
| Peritoneum | 1 (17) |
| Number of metastatic sites - no. (%) | |
| 1 | 3 (50) |
| 2 | 3 (50) |
| Primary tumor resection - no. (%) | |
| Yes | 4 (67) |
| No | 2 (33) |
| CEA - no. (%) | |
| ≤5 ng/mL | 1 (17) |
| >5 ng/mL | 5 (83) |
| Chemotherapy regimen - no. (%) | |
| mFOLFOX6 | 4 (67) |
| FOLFIRI | 1 (17) |
| 5-FU/LV | 1 (17) |
| Antibody - no. (%) | 3 (50) |
| Anti-EGFR | 3 (50) |
| Cetuximab | 2 (33) |
| Panitumumab | 1 (17) |